Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Sacubitril/valsartan reduces serum uric acid concentration, in PARADIGM-HF

Next Previous
Trial Profile

Sacubitril/valsartan reduces serum uric acid concentration, in PARADIGM-HF

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 28 Aug 2023 Results presented at the ESC Congress 2023 - Annual Congress of the European Society of Cardiology
  • 16 Jun 2022 Results assessing prescription rate of conventional medical therapy and its association with long-term outcomes using enrollment criteria from PARADIGM-HF/DAPA-HF and SHIFT trials published in the International Journal of Cardiology
  • 03 Dec 2021 Data was used from this trial to develop a Markov model assessing projected Health Outcomes with Real-World Versus Optimal Usage of Sacubitril/Valsartan in Portugal presented at the 24th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top